True Stevens Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) from CTLA-4 and PD-1/PD-L1 inhibitors are rare but they portend poor prognosis with mortality rates of 10% for SJS and 50% for TEN (6, 18). This evidence concerns the gene CD274 and toxic epidermal necrolysis.